Advanced search
Publication Cover
Expert Review of Vaccines Volume 3, 2004 - Issue 1
Submit an article Journal homepage
162
Views
119
CrossRef citations to date
0
Altmetric
Review

Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens

Joseph U Igietseme Molecular Pathogenesis laboratory, National Center for Infectious Disease, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Mailstop C17, Atlanta, GA 30333 USA. [email protected]
,
Francis O Eko Molecular Pathogenesis laboratory, National Center for Infectious Disease, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Mailstop C17, Atlanta, GA 30333 USA. [email protected]
,
Qing He Molecular Pathogenesis laboratory, National Center for Infectious Disease, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Mailstop C17, Atlanta, GA 30333 USA. [email protected]
&
Carolyn M Black Molecular Pathogenesis laboratory, National Center for Infectious Disease, Centers for Disease Control and Prevention (CDC), 1600 Clifton Road, Mailstop C17, Atlanta, GA 30333 USA. [email protected]
Pages 23-34 | Published online: 09 Jan 2014

References

  • Ismail N, Olano JP, HM Feng, DH Walker. Current status of immune mechanisms of killing of intracellular microorganisms. FENIS Microbial Lett. 207(2), 111–120 (2002).
  • Plotkin SA. Immunologic correlates of protection induced by vaccination. Pediatr. Infect. Dis. 20(1), 63–75 (2001).
  • Moore T, Ekworomadu C, Eko F et al. Fc receptor-mediated antibody regulation of T-cell immunity against intracellular pathogens. J. Infect. Dis. 188(4), 617–624 (2003).
  • ••Confirms that antibodies of specificisotypes enhance Thl activation against intracellular pathogens.
  • Arulanandarn B, Raeder R, Nedrud JG et al. IgA Immunodeficiency leads to Inadequate Th cell priming and increased susceptibility to influenza virus infection. J. Immunol 166,226–231 (2001).
  • •Report revealed that antibodies of the IgA isotype enhance Thl activation against viruses.
  • Guyre PM, Graziano RF, Goldstein J et al. Increased potency of Fc-receptor-targeted antigens. Cancer Immunot Immunother. 45, 146–148 (1997).
  • •One of the first reports revealing that antibodies are capable of enhancing T cell response via FcR mechanisms.
  • Mackaness GB. Resistance to intracellular infection. J. Infect. Dis. 123,439415 (1971).
  • Collins FM. Cellular antimicrobial immunity. Crit. Rev. Microbial 7, 27–91 (1978).
  • Dorman SE, Holland SM. Interferon-y and interleukin-12 pathway defects and human disease. Cytokine Growth Factor Rev. 11(4), 321–333 (2000).
  • •Recent finding of heightened susceptibility of humans to mycobacterial and intracellular pathogens due to mutations in certain ml cytokines, especially IL-12 and IFN-y.
  • Igietseme JU, Eko FO, Black CM. Contemporary approaches to designing and evaluating vaccines against Chlamydia. Expert Rev. Vaccines 2(1), 129–146 (2003).
  • Morrison RR Caldwell HD. Immunity to rnurine chlamydial genital infection. Infect. Immun. 70(6), 2741–2751 (2002).
  • Loomis PW, Stambach MN. T cell responses to Chlamydia trachomatis. Curr. Opin. Microbial 5,87–91 (2002).
  • Cooper A, Dalton D, Stewart T et al. Disseminated tuberculosis in interferon-y gene-disrupted mice. J. Exp. Med. 178(6), 2243–2247 (1993).
  • •The requirement for T-cell-derived IFN-y for host control of mycobacterial infection.
  • Unanue, E, Inter-relationship among macrophages, natural killer cells and neutrophils in early stages ofListeria resistance. Curn Opin. Immund 9(1), 35–43 (1997).
  • Hess J, Ladel C, Miko D, Kaufmann S. Salmonella typhirnurium aroA- infection in gene-targeted immunodeficient mice: major role of CD4. TCR-a,13 cells and IFN-y in bacterial clearance independent of intracellular location.' Immunot 156(9), 3321–3326 (1996).
  • •The requirement for T-cell-derived IFN-y for host control of salmonella infection.
  • Walker D, Olano J, Feng H. Critical role of cytotoxic T lymphocytes in immune clearance of rickettsial infection. Infect. Immun. 69(3), 1841–1846 (2001).
  • •The demonstration of a critical role of CTLs in host control of rickettsial infection.
  • Rank RG. Models of immunity. In Chlamydia: Intracellular Biology Pathogenesis and Immunity. Stephens RS (Ed.), ASM Press, DC, USA 239–295 (1999).
  • Rank RG. Animal models of urogenital infections. Methods Enzymol 235,83–93 (1994).
  • Feng H, Popov V, Yuoh G, Walker D. Role of T lymphocyte subsets in immunity to spotted fever group Rickettsiae. J. Immunol 158(11), 5314–5320 (1997).
  • Morrison SG, Su H, Caldwell HD, Morrison RP Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD(.) T cells but not CD8(') T cells. Infect. Immun. 68(12), 6979–6987 (2000).
  • Rottenberg ME, Gigliotti-Rothfuchs A, Wigzell H. The role of IFN-y in the outcome of chlamydial infection. Curr. Opin. Immunol 14(4), 444 451 (2002).
  • Byrne GI, Lehmann LK, Landry GJ. Induction of tryptophan catabolism is the mechanism for y interferon-mediated inhibition of intracellular Chlamydia psittaci replication in T24 cells. Infect. Immun. 53,347-351 (1986).
  • Holtmann H, Shemer-Avni Y, Wessel K, Sarov I, Wallach D. Inhibition of growth of Chlamydia trachomatis by tumor necrosis factor is accompanied by increased prostaglandin synthesis. Infect. Immun. 58, 3168–3172 (1990).
  • Kaufmann SHE. Immunity to intracellular bacteria. Annu. Rev. Immunot 11, 29–163 (1993).
  • Zhong G, de la Maza LM. Activation of mouse peritoneal macrophages in vitro or in vivo by recombinant murine y-interferon inhibits the growth of Chlamydia trachomatis serovar Ll. Infect. Immun. 56, 3322–3325 (1988).
  • Feng H, Walker D. Mechanisms of intracellular killing of Rickettsia conorii in infected human endothelial cells, hepatocytes, and macrophages. Infect. Immun. 68(12), 6729–6736 (2000).
  • MacKenzie C, Gonzalez R, Kniep E, Roch S, Daubener W Cytokine mediated regulation of interferon-y-induced IDO activation. Adv. E. Med. Biol. 467, 533–539 (1999).
  • Daubener W MacKenzie C. IFN-y activated indoleamine 2,3-dioxygenase activity in human cells is an antiparasitic and an antibacterial effector mechanism. Adv. Exp. Med. Biol. 467,517-524 (1999).
  • Chen B, Stout R, Campbell WF. Nitric oxide production: a mechanism of Chlamydia trachomatis inhibition in interferon-y-treated RAW264.7 cells. FEMS Immunot Med. Microbial 14(2–3), 109–120 (1996).
  • Bogdan C. Nitric oxide and the immune response. Nat. Immunot 2(10), 907–916 (2001).
  • Bogdan C, Rollinghoff M, Diefenbach A. Reactive oxygen and reactive nitrogen intermediates in innate and specific immunity. Curr. Opin. Immunot 12(1), 64–76 (2000).
  • Barnewall R, Rikihisa Y. Abrogation of y interferon-induced inhibition of Ehrlichia chaffeensis infection in human monocytes with iron-transferrin. Infect. Immun. 62(11), 4804 4810 (1994).
  • Byrd TF, MA Horwitz. Regulation of transfenin receptor expression and fenitin content in human mononuclear phagocytes. Coordinate upregulation by iron transfenin and downregulation by interferon-y.1 Clin. Invest. 91,969-976 (1993).
  • Edelson B, Cossart P, Unanue E. Paradigm revisited: antibody provides resistance to Listeria infection.' Immunol163(8), 4087–4090 (1999).
  • Caldwell HD, Perry U. Neutralization of Chlamydia trachomatis infectivity with antibodies to the major outer membrane protein. Infect. Immun. 38,745–754(1982).
  • Zhang Y-X, Stewart SJ, Caldwell HD. Protective monoclonal antibodies to Chlamydia trachomatis serovar- and serogroup-specific major outer membrane protein determinants. Infect. Immun. 57, 636–638 (1989).
  • Edelson B, Unanue E. Intracellular antibody neutralizes Listeria growth. Immunity 14(5), 503–512 (2001).
  • Cotter TW, Meng Q, Shen Z-L, et al. Protective efficacy of outer membrane protein-specific immunoglobulin (IA and IgG monoclonal antibodies in a murine model of Chlamydia trachomatis genital tract infection. Infect. Immun. 63, 4704 4714 (1995).
  • Mazanec MB, Nedrud JG, Kaetzel CS, Lamm ME. A three-tiered view of the role of IgA in mucosal defense. Immunot Today 14,430–435 (1993).
  • Corthesy B, Spertini E Secretory immunoglobulin A: from mucosal protection to vaccine development. Biol. Chem. 380(11), 1251–1262 (1999).
  • Brandtzaeg P Mucosal immunity: integration between mother and the breast-fed infant. Vaccine 21(24), 3382–3388 (2003).
  • Li J, Yager E, Reilly Metal. Outer membrane protein-specific monoclonal antibodies protect SCID mice from fatal infection by the obligate intracellular bacterial pathogen Ehrlichia chaffeensis. Immunot 166(3), 1855–1862 (2001).
  • Casadevall A, Pirofski L Antibody- mediated regulation of cellular immunity and the inflammatory response. Trends Immunot 24(9), 474 478 (2003).
  • Casadevall A. Antibody-mediated immunity against intracellular pathogens: two-dimensional thinking comes full circle. Infect. Immun. 71(8), 4225–4228 (2003).
  • •A review of the role of antibodies in controlling intracellular pathogens that involves targeting the extracellular phase of certain microbes.
  • Burton DR, Parren PWHI. Vaccines and the induction of functional antibodies: time to look beyond the molecules of natural infection? Nat. Med. 6(2), 123–125 (2000).
  • Moore T, Ananaba GA, Bolier J et al. Fc Receptors regulation of protective immunity against Chlamydia trachomatis. Immunology 105(2), 213–221 (2002).
  • •The first report suggesting that the requirement for antibodies for optimal memory T-cell response is related to FcR-mediated functions of antibodies.
  • Brunham RC, Cohen CR, Kimani J, Bwayo J, Plummer E Typel/Type2 immunity and Chlamydia trachomatis: insights from the influence of HIV, In: Chlamydial Infections. Schachter J, Saikku P, Stephens R, Rank RG (Eds.), University press, Antayla, Turkey, 202 (2002).
  • Szabo S, Dighe A, Gubler U, Murphy K. Regulation of the interleukin (IL)-12R 0–2 subunit expression in developing T helper (Th)1 and Th2 cells. Exp. Med. 185(5), 817–824 (1997).
  • Jefferies C, O'Niell LAJ. Signal transduction pathway activated by Toll-like receptors. Mod. Asp. Immunobial 2(4), 169–175 (2002).
  • Dabbagh K, Lewis D. Toll-like receptors and T-helper-1/T-helper-2 responses. Curr. Opin. Infect. Dis. 16(3), 199–204 (2003).
  • Underhill D. Toll-like receptors: networking for success. Eur. j Immunot 33(7), 1767–1775 (2003).
  • Kaisho T, Akira S. Regulation of dendritic cell function through Toll-like receptors. Curr. Mot Med. 3(4), 373–385 (2003).
  • Park A, Scott P. IL-12: keeping cell- mediated immunity alive. Scand. Immunot 53(6), 529–532 (2001).
  • Lezzi G, Scotet E, Scheidegger D, Lanzavecchia A. The interplay between the duration of TCR and cytokine signaling determines T-cell polarization. Eur. Immunot 29,4029–4101 (1999).
  • Lu H, Zhong G. Interleukin-12 production is required for chlamydial antigen-pulsed dendritic cells to induce protection against live Chlamydia trachomatis infection. Infect. Immun. 67(4), 1763–1769 (1999).
  • •The first experimental evidence for the requirement of IL-12 in chlamydial immunity.
  • Igietseme JU, Ananaba GA, Boller J et al. Suppression of endogenous IL-10 gene expression in dendritic cells enhances antigen presentation for enhanced specific Thl induction: potential for cellular vaccine development." Immunot 164(4), 4212–4219 (2000).
  • ••A demonstration of the impact of adeficiency of endogenous IL-10 on Thi activation and the application of this process in vaccine design against pathogens (and possibly tumors) that require elevated Thl activation.
  • Gherardi M, Ramirez J, Esteban M. Towards a new generation of vaccines: the cytokine IL-12 as an adjuvant to enhance cellular immune responses to pathogens during prime-booster vaccination regimens. Histol. Histopathol 16(2), 655–667 (2001).
  • Villinger E Cytokines as clinical adjuvants: how far are we? Expert. Rev. Vaccines 2(2), 317–326 (2003).
  • Fieschi C, Casanova J. The role of interleukin-12 in human infectious diseases: only a faint signature. Eur. Immunot 33(6), 1461–1464 (2003).
  • Heinzel FP, Schoenhaut DS, Rerko RM, Rosser LE, Gately MK. Recombinant interleukin 12 cures mice infected with Leishmania major. j Exp. Med. 177(5), 1505–1509 (1993).
  • Sypek JP, Chung CL, Mayor SE et al. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. j E. Med. 177 (6), 1797–1802 (1993).
  • Neighbors M, Xu X, Barrat F et al. A critical role for interleukin 18 in primary and memory effector responses to Listeria monocytogenes that extends beyond its effects on interferon y production. J Exp. Med. 194(3), 343–354 (2001).
  • Su H, Parnell M, Caldwell HD. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against genital tract infection. Vaccine 13(11), 1023–1032 (1995).
  • Bailey RL, Kajbaf M, Whittle HC, Ward ME, Mabey DC. The influence of local antichlamydial antibody on the acquisition and persistence of human ocular chlamydial infection: IgG antibodies are not protective. Epidemiol Infect. 111(2), 315–324 (1993).
  • Johansson M, Schon K, Ward M, Lycke N. Studies in knockout mice reveal that anti-chlamydial protection requires Thl cells producing IFN-y: is this true for human? Scanei I Immunot 46(6), 546–552 (1997).
  • Cohen CR, Nguti R, Bukusi EA et al.Human immunodeficiency virus type 1-infected women exhibit reduced interferon-y after Chlamydia trachomatis stimulation of peripheral lymphocytes. J. Infect. Dis. 182(6), 1672–1677 (2000).
  • Johansson M, Schon K, Ward M, Lycke N. Genital tract infection with Chlamydia trachomatis fails to induce protective immunity in y-interferon receptor-deficient mice despite a strong local immunoglobulin A response. Infect. Immun. 65(3), 1032–1044 (1997).
  • Cotter TW, Ramsey KH, Miranpuri GS, Poulsen CE, Byrne GI. Dissemination of Chlamydia trachomatis chronic genital tract infection in y interferon gene knockout mice. Infect. Immun. 65(6), 2145–2152 (1997).
  • Igietseme JU, Black CM, Caldwell HD. Chlamydia vaccine: strategies and status. Bio. Drugs 16(1), 19-35(2002).
  • Igietseme JU, Ananaba GA, Candal DH, Lyn D, Black CM. Immune control of chlamydial growth in the human epithelial cell line RT4 involves multiple mechanisms that include nitric oxide induction, tryptophan catabolism and iron deprivation. Microbial Immunol 42(9), 617–625 (1998).
  • Igietseme JU, Rank RG. Susceptibility to reinfection after a primary chlamydial genital infection is associated with a decrease of antigen-specific T cells in the genital tract. Infect. Immun. 59,1346–1351 (1991).
  • Su H, Feilzer K, Caldwell HD, Morrison RP. Chlamydia trachomatis genital tract Infection of antibody-deficient gene knockout mice. Infict. Immun. 65(6), 1993–1999 (1997).
  • •One of the initial evidence that memory T-cell response is diminished during reinfections in the absence of specific antichlamydial antibodies.
  • Yang X, Brunharn RC. Gene knockout B cell-deficient mice demonstrate that B cells play an important role in the initiation of T cell responses to Chlamydia trachomatis (mouse pneumonitis) lung infection. j Immunol 161(3), 1439–1446 (1998).
  • •One of the initial evidence that memory T-cell response is diminished during reinfections in the absence of specific antichlamydial antibodies.
  • Caron E, Hall A. Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science 282(5394), 1717–1721 (1998).
  • Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immund 166,7381–7388 (2001).
  • Geissmann F, LauunayP, Pasquier B et al. A subset of human dendritic cells expresses IgA Fc receptor (CD89), which mediates internalization and activation upon cross-linking by IgA complexes.' Immunot 166, 346–352 (2001).
  • Lanzavecchia A. Mechanisms of antigen uptake for presentation. Curr. Opin. Immunol 8(3), 348–354 (1996).
  • Regnault A, Lankar D, Lacabanne Vet al. Fcy receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189(2), 371–380 (1999).
  • Gosselin EJ, Wardwell K, Gosselin DR, et al. Enhanced antigen presentation using human Fcy receptor (monocyte/macrophage)-specific immunogens." Immund 149,3477–3481 (1992).
  • Fanger NA, Vogitlaender D, Liu C et al. Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor (CD64) expressed on human blood dendritic cells. Immunot 158,3090–3098 (1997).
  • Bell D, Young JW, Banchereau J. Dendritic cells. Adv. Immunot 72,255–324 (1999).
  • Guermonprez P, Valladeau J, Zitvogel L, Thery C, Anrigorena C. Antigen presentation and T cell stimulation by dendritic cells. Ann. Rev. Immunol 20, 621–667 (2002).
  • Ojcius DM, Bravo de Alba Y, Kanellopoulos JM et al. Internalization of Chlamydia by dendritic cells and stimulation of Chlamydia-specific T cells." Immund 160(3), 12970–1303 (1998).
  • Su H, Messer R, Whitmire W, et al. Vaccination against chlamydial genital tract infection after immunization with dendritic cells pulsed ex vivo with nonviable chlamydiae.j Exp. Med 188(5), 809–818 (1998).
  • Stagg AJ, Stackpoole A, Elsley WJ, Knight SC. Acquisition of chlamydial antigen by dendritic cells and monocytes. Adv. E. Med. Bid 329,581–586 (1993).
  • Stagg AJ, Tuffrey M, Woods C, Wunderink E, Knight SC. Protection against ascending infection of the genital tract by Chlamydia trachomatis is associated with recruitment of major histocompatibility complex class II antigen-presenting cells into uterine tissue. Infect. Immun. 66(8), 3535–3544 (1998).
  • Wen YM, Qu D, Zhou SH. Antigen-antibody complex as therapeutic vaccine for viral hepatitis B. Intern. Rev. Immund 18, 251–258 (1999).
  • Heyman B. Feedback regulation by IgG antibodies. Immund Lett. 88(2), 157–161 (2003).
  • Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. j Immund 166(2), 1141-1147(2001).
  • Ravetch JV, Bolland S. IgG Fc Receptors. Ann. Rev. Immund 19,275–290 (2001).
  • Hamano Y, Arase H, Saisho H, Saito T. Immune complex and Fc receptor-mediated augmentation of antigen presentation for in vivo Th cell responses. J. Immund 164,6113–6119 (2000).
  • Amigorena S, Bonnerot C. Fc receptor signaling and trafficking: a connection for antigen processing. Immund Rev. 172, 279–284 (1999).
  • Amigorena S, Bonnerot C. Fc receptors for IgG and antigen presentation on MHC class I and class II molecules. Semin. Immund 11, 385–390 (1999).
  • Rao A, Avni 0. Molecular aspects of T-cell differentiation. Br. Med Bull 56(4), 969–984 (2000).
  • Wurster AL, Tanaka T, Grusby MJ. The Biology of Stat4 and Stat6. Oncogene 19(21), 577–2584 (2000).
  • Murphy KM, Ouyang J, Farrar D et al. Signaling and transcription in T helper development. Ann. Rev. Immund 18, 451–494 (2000).
  • Cohen BE, Rosenthal AS, Paul WE. Antigen—macrophage interaction. II. Relative roles of cytophilic antibody and other membrane sites. J. Immund 111, 820–828 (1973).
  • Chang TW Regulation of immune response by antibodies: the importance of antibody and monocyte Fc receptor interaction in T cell activation. Immund Today 6,245 (1985).
  • Manca F, Fenoglio D, Kunkl A. Differential activation of T cell clones stimulated by macrophages exposed to antigen complexed with monoclonal antibodies. J. Immund 140,2893–2898 (1988).
  • •One of the first in vitro observations that antigen delivery via antibodies could lead to an enhanced T-cell activation.
  • Pieters J. MHC class II-restricted antigen processing and presentation. Adv. Immund 75,159–208 (2000).
  • Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nature Immund 1(3), 199–205 (2000).
  • Heijnen IA, van Vugt MJ, Fanger NA et al. Antigen targeting to myeloid-specific human FcyRI/CD64 triggers enhanced antibody responses in transgenic mice. J. Clin. Invest. 97(2), 331–338 (1996).
  • igietSeMe JU, Eko FO, Ananaba GA, et d Immunologic basis for the protective efficacy of chlamydia vaccines and the mechanism of T and B cell co-operaton in chlamydia immunity. In: Chlamydia Infictions. Schachter J, Saikku P, Stephens R (Eds.), University press, Antalya, Turkey 400–415 (2002).
  • Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG Oligodeoxynucleotides acts as adjuvants that switch on T-helper (Th)1 immunity." Exp. Med. 186,1623-1631 (1997).
  • Klinman DM, Barnhart KM, Conover J. CpG motifs as immune adjuvants. Vaccine 17(1), 19–25 (1999).
  • Carson DA, Raz E. Oligonucleotide adjuvants for T helper (Th)l-specific vaccination." E. Med 186,1621–1622 (1997).
  • Huang L-Y, Sousa CR, Itoh Y, Inman J, Scott DE IL-12 induction by a Thl-inducing adjuvant in vivo: dendritic cell subsets and regulation by IL-10. J. Immund 167,1423–1430 (2001).
  • Schijns VE. Antigen delivery systems and imrnunostimulation. Vet. Immund Immunopathol. 87,195–198 (2002).
  • Kersten GFA, Crommelin DJA. Liposomes and ISCOMS as vaccine formulations. Biochim. Biophys. Acta1241, 117–138 (1995).
  • Singh M, °Eagan D. Advances in vaccine adjuvants. Nat. Biotechnd 17(11), 1075–1081 (1999). no de la Maza LM, Peterson EM. Vaccines for Chlamydia trachomatis infections. Cun: Opin. Investig. Drugs 3(7), 980–986 (2002).
  • Flynn,JL and Chan,J. Immunology of tuberculosis. Ann. Rev. Immund 19, 93–129 (2001).
  • Mazurek GH, LoBue PA, Daley CL et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JANIA 14, 1740–1747 (2003).
  • Casanova JL, Abel L Genetic dissection of immunity to mycobacteria: the human model. Ann. Rev. Immund 20,581–620 (2002).
  • ••Genetic evidence for a crucial of Thl.-related cytokines in protective immunity against mycobacterial infections.
  • MacMicking JD, Taylor GA, McKinney JD. Immune Control of tuberculosis by IFN-y-inducible LRG-47. Science 302, 654–659 (2003).
  • Website to accompany [114].

Websites

  • www.ncbi.nlm.nih.govientrez/query.fcgi?c md=Retrieve8cdb=PubMed8clist_uids=115 948998thopt=Abstract.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.